

Correction

Open Access

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Paul D Carey*¹, Bavanisha Vythilingum¹, Soraya Seedat¹,
Jacqueline E Muller¹, Michael van Ameringen² and Dan J Stein¹

Address: ¹MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa and ²Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada

Email: Paul D Carey* - pcarey@sun.ac.za; Bavanisha Vythilingum - bv@sun.ac.za; Soraya Seedat - sseedat@sun.ac.za; Jacqueline E Muller - jemuller@sun.ac.za; Michael van Ameringen - vanamer@mcmaster.ca; Dan J Stein - djs2@sun.ac.za

* Corresponding author

Published: 30 November 2005

Received: 25 November 2005

BMC Psychiatry 2005, **5**:44 doi:10.1186/1471-244X-5-44

Accepted: 30 November 2005

This article is available from: <http://www.biomedcentral.com/1471-244X/5/44>

© 2005 Carey et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The comment in the introduction of our article [1] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT_{1D} effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [2].

References

1. Carey PD, Vythilingum B, Seedat S, Muller JE, van AM, Stein DJ: **Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]**. *BMC Psychiatry* 2005, **5**:5.
2. Richelson E, Souder T: **Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds**. *Life Sci* 2000, **68**:29-39.